KR101345471B1 - Process for Preparing 3,4-Dihydroquinazoline Derivative and Intermediate therefor - Google Patents

Process for Preparing 3,4-Dihydroquinazoline Derivative and Intermediate therefor Download PDF

Info

Publication number
KR101345471B1
KR101345471B1 KR1020110023369A KR20110023369A KR101345471B1 KR 101345471 B1 KR101345471 B1 KR 101345471B1 KR 1020110023369 A KR1020110023369 A KR 1020110023369A KR 20110023369 A KR20110023369 A KR 20110023369A KR 101345471 B1 KR101345471 B1 KR 101345471B1
Authority
KR
South Korea
Prior art keywords
formula
reaction
compound
process according
acid
Prior art date
Application number
KR1020110023369A
Other languages
Korean (ko)
Other versions
KR20120105744A (en
Inventor
이재열
주동준
이경태
김영덕
오천림
Original Assignee
동우신테크 주식회사
경희대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 동우신테크 주식회사, 경희대학교 산학협력단 filed Critical 동우신테크 주식회사
Priority to KR1020110023369A priority Critical patent/KR101345471B1/en
Publication of KR20120105744A publication Critical patent/KR20120105744A/en
Application granted granted Critical
Publication of KR101345471B1 publication Critical patent/KR101345471B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/78Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

본 발명은 경제적이고 효율적으로 3,4-디히드로퀴나졸린 유도체를 제조하는 방법 및 이를 위한 신규한 중간체에 관한 것이다.The present invention relates to a process for producing 3,4-dihydroquinazolin derivatives economically and efficiently and to novel intermediates therefor.

Description

3,4-디히드로퀴나졸린 유도체의 제조방법 및 이를 위한 중간체 {Process for Preparing 3,4-Dihydroquinazoline Derivative and Intermediate therefor}Process for preparing 3,4-dihydroquinazoline derivatives and intermediates therefor {Process for Preparing 3,4-Dihydroquinazoline Derivative and Intermediate therefor}

본 발명은 3,4-디히드로퀴나졸린 유도체의 제조방법 및 이를 위한 중간체에 관한 것이다. 보다 구체적으로, 본 발명은 경제적이고 효율적으로 3,4-디히드로퀴나졸린 유도체를 제조하는 방법 및 이를 위한 신규한 중간체에 관한 것이다.The present invention relates to a process for the preparation of 3,4-dihydroquinazoline derivatives and intermediates therefor. More specifically, the present invention relates to a process for producing 3,4-dihydroquinazoline derivatives economically and efficiently and to novel intermediates therefor.

하기 화학식 1의 3,4-디히드로퀴나졸린 유도체는 본 발명자들에 의해 개발된 화합물로서 T-형 칼슘채널 차단을 통하여 우수한 항암 효과를 나타내는 것으로 보고된 바 있다[참고문헌: 한국 특허 제10-0902145호].3,4-dihydroquinazoline derivative of the general formula (1) is a compound developed by the present inventors has been reported to exhibit an excellent anti-cancer effect through T-type calcium channel blocking [Reference: Korean Patent No. 10- 0902145].

[화학식 1][Formula 1]

Figure 112011019160272-pat00001
Figure 112011019160272-pat00001

상기 화합물은 하기 반응식 1에 개시된 방법에 의해 제조될 수 있는 것으로 알려져 있다.It is known that the compound can be prepared by the method disclosed in Scheme 1 below.

[반응식 1][Reaction Scheme 1]

Figure 112011019160272-pat00002
Figure 112011019160272-pat00002

그러나 상기 방법은 중간체인 아자포스포란(iii)이 완벽히 분리하여 장시간 보관하기에 매우 불안정하고, 아자포스포란과의 반응에 쓰이는 4-바이페닐일 이소시아네이트가 매우 비싼 시약이고 반응 혼합물의 정제방법 또한 대량생산 과정에서 피해야 할 컬럼 크로마토그래피를 이용하는 문제점이 있었다. 또한 마지막 단계인 벤질기의 제거 및 환원아미노화 반응(reductive amination)을 위해 장시간이 소요되는 문제점이 있었다.However, this method is very unstable for long time storage of the intermediate azaphosphoran (iii) completely separated, 4-biphenylyl isocyanate used for the reaction with azaphosphoran is a very expensive reagent and the purification method of the reaction mixture is also a large amount There was a problem using column chromatography to be avoided in the production process. In addition, there is a problem that takes a long time for the final step of removing the benzyl group and the reduction amination reaction (reductive amination).

본 발명자들은 3,4-디히드로퀴나졸린 유도체의 합성에 있어 상기한 문제점을 해결하고자 예의 연구 검토한 결과, 3,4-디히드로퀴나졸린 유도체를 보다 효율적이고 경제적으로 제조할 수 있는 새로운 방법을 개발하였다.The present inventors have studied diligently to solve the above problems in the synthesis of 3,4-dihydroquinazoline derivatives, a new method that can be produced more efficiently and economically to 3,4-dihydroquinazoline derivatives Developed.

따라서, 본 발명의 목적은 3,4-디히드로퀴나졸린 유도체를 경제적이고 효율적으로 제조하는 방법을 제공하는 것이다.Accordingly, it is an object of the present invention to provide a method for economically and efficiently preparing 3,4-dihydroquinazolin derivatives.

본 발명의 다른 목적은 3,4-디히드로퀴나졸린 유도체의 제조를 위한 신규한 중간체를 제공하는 것이다.Another object of the present invention is to provide novel intermediates for the preparation of 3,4-dihydroquinazoline derivatives.

본 발명은 하기 화학식 1의 3,4-디히드로퀴나졸린 유도체의 제조방법에 관한 것으로, 본 발명의 제조방법은The present invention relates to a method for preparing a 3,4-dihydroquinazoline derivative of the following formula (1),

(i) 하기 화학식 2의 2-니트로신나믹엑시드를 메탄올과 에스테르화 반응시킨 다음, 니트로기를 환원 반응시켜 하기 화학식 3의 메틸 2-아미노신나메이트를 수득하는 단계;(i) esterifying the 2-nitrocinnamic acid of Formula 2 with methanol and then reducing the nitro group to obtain methyl 2-aminocinnamate of Formula 3;

(ii) 하기 화학식 3의 메틸 2-아미노신나메이트를 바이페닐-4-카르복실산 및 디페닐포스포릴 아자이드와 반응시켜 하기 화학식 4의 우레아 화합물을 수득하는 단계;(ii) reacting methyl 2-aminocinnamate of Formula 3 with biphenyl-4-carboxylic acid and diphenylphosphoryl azide to obtain a urea compound of Formula 4;

(iii) 하기 화학식 4의 우레아 화합물을 탈수반응시켜 하기 화학식 5의 카보디이미드 화합물을 수득하는 단계;(iii) dehydrating the urea compound of formula 4 to obtain a carbodiimide compound of formula 5;

(iv) 하기 화학식 5의 카보디이미드 화합물을 하기 화학식 6의 디아민과 반응시켜 하기 화학식 7의 디히드로퀴나졸린 에스테르 화합물을 수득하는 단계; 및(iv) reacting a carbodiimide compound of formula 5 with a diamine of formula 6 to obtain a dihydroquinazolin ester compound of formula 7; And

(v) 하기 화학식 7의 디히드로퀴나졸린 에스테르 화합물을 벤질아민과 반응시키는 단계를 포함한다.(v) reacting the dihydroquinazolin ester compound of formula (7) with benzylamine.

[화학식 2](2)

Figure 112011019160272-pat00003
Figure 112011019160272-pat00003

[화학식 3](3)

Figure 112011019160272-pat00004
Figure 112011019160272-pat00004

[화학식 4][Chemical Formula 4]

Figure 112011019160272-pat00005
Figure 112011019160272-pat00005

[화학식 5][Chemical Formula 5]

Figure 112011019160272-pat00006
Figure 112011019160272-pat00006

[화학식 6][Chemical Formula 6]

Figure 112011019160272-pat00007
Figure 112011019160272-pat00007

[화학식 7][Formula 7]

Figure 112011019160272-pat00008
Figure 112011019160272-pat00008

[화학식 1][Formula 1]

Figure 112011019160272-pat00009
Figure 112011019160272-pat00009

이하, 본 발명의 제조방법을 하기 반응식 2를 참조로 보다 상세히 설명한다.Hereinafter, the production method of the present invention will be described in more detail with reference to Scheme 2 below.

[반응식 2][Reaction Scheme 2]

Figure 112011019160272-pat00010

Figure 112011019160272-pat00010

제1단계 : 화학식 3의 메틸 2-아미노신나메이트의 합성First Step: Synthesis of Methyl 2-aminocinnamate of Formula 3

화학식 3의 메틸 2-아미노신나메이트는 화학식 2의 2-니트로신나믹엑시드를 메탄올과 에스테르화 반응시킨 다음, 니트로기를 환원 반응시켜 제조한다.Methyl 2-aminocinnamate of Formula 3 is prepared by esterifying 2-nitrocinnamic acid of Formula 2 with methanol and then reducing the nitro group.

상기 에스테르화 반응은 산 촉매의 존재하에 수행하는 것이 바람직하다. 산 촉매로는 황산, 염산, 질산 등이 사용될 수 있으나, 이에 제한되는 것은 아니다. 반응 온도는 메탄올의 환류조건이 가장 바람직하다.The esterification reaction is preferably carried out in the presence of an acid catalyst. As the acid catalyst, sulfuric acid, hydrochloric acid, nitric acid, etc. may be used, but is not limited thereto. The reaction temperature is most preferably the reflux condition of methanol.

또한 니트로기의 환원 반응은 이중결합의 환원을 피하기 위하여 특히 SnCl2H2O를 사용하는 것이 바람직하다. 반응 용매로는 에틸 아세테이트 등이 사용될 수 있다.
In addition, in order to avoid the reduction of the double bond, the reduction reaction of the nitro group is particularly preferable to use SnCl 2 ˙ 2H 2 O. Ethyl acetate may be used as the reaction solvent.

제2단계 : 화학식 4의 우레아 화합물의 합성Second Step: Synthesis of Urea Compound of Formula 4

화학식 3의 메틸 2-아미노신나메이트를 바이페닐-4-카르복실산 및 디페닐포스포릴 아자이드(diphenylphosphoryl azide: DPPA)와 반응시키면 커티어스 전위반응(Curtius rearrangement)에 의해 화학식 4의 우레아 화합물이 생성된다.When methyl 2-aminocinnamate of formula 3 is reacted with biphenyl-4-carboxylic acid and diphenylphosphoryl azide (DPPA), the urea compound of formula 4 is obtained by Curtius rearrangement. Is generated.

상기 반응은 염기의 존재하에 수행하는 것이 바람직하다. 염기로는 트리에틸아민, 디이소프로필에틸아민 등이 사용될 수 있으나, 이에 제한되는 것은 아니다. 반응 용매로는 톨루엔, 자일렌, 벤젠 등이 사용될 수 있으며, 반응 온도는 상온 내지 100℃가 바람직하다.
The reaction is preferably carried out in the presence of a base. Triethylamine, diisopropylethylamine, etc. may be used as the base, but is not limited thereto. Toluene, xylene, benzene and the like may be used as the reaction solvent, and the reaction temperature is preferably from room temperature to 100 ° C.

제3단계 : 화학식 5의 카보디이미드 화합물의 합성Third Step: Synthesis of Carbodiimide Compound of Formula 5

화학식 5의 카보디이미드 화합물은 화학식 4의 우레아 화합물을 탈수반응시켜 제조한다.The carbodiimide compound of Formula 5 is prepared by dehydrating the urea compound of Formula 4.

상기 탈수반응은 PPh3·Br2 또는 CBr4/Ph3P과 Et3N의 존재하에 수행한다.The dehydration reaction is carried out in the presence of PPh 3 · Br 2 or CBr 4 / Ph 3 P and Et 3 N.

반응 용매로는 메틸렌클로라이드, 클로로포름 등이 사용될 수 있으며, 반응 온도는 0 ℃가 바람직하다.
Methylene chloride, chloroform and the like may be used as the reaction solvent, and the reaction temperature is preferably 0 ° C.

제4단계 : 화학식 7의 디히드로퀴나졸린 에스테르 화합물의 합성Fourth Step: Synthesis of Dihydroquinazoline Ester Compound of Formula 7

화학식 5의 카보디이미드 화합물을 화학식 6의 디아민과 반응시키면 연속적인 친핵첨가 반응과 분자내 컨쥬게이트 첨가 반응을 통해 화학식 7의 디히드로퀴나졸린 에스테르 화합물이 생성된다.Reaction of the carbodiimide compound of formula 5 with the diamine of formula 6 produces a dihydroquinazolin ester compound of formula 7 through a continuous nucleophilic reaction and intramolecular conjugate addition reaction.

반응 용매로는 톨루엔, 벤젠 등이 사용될 수 있으며, 반응 온도는 상온이 바람직하다.
Toluene, benzene and the like may be used as the reaction solvent, and the reaction temperature is preferably room temperature.

제5단계 : 화학식 1의 디히드로퀴나졸린 유도체의 합성Step 5: Synthesis of Dihydroquinazoline Derivative of Formula 1

화학식 1의 디히드로퀴나졸린 유도체는 화학식 7의 디히드로퀴나졸린 에스테르 화합물을 벤질아민과 반응시켜 제조한다.Dihydroquinazoline derivatives of Formula 1 are prepared by reacting the dihydroquinazoline ester compound of Formula 7 with benzylamine.

상기 반응은 1,5,7-트리아자바이시클로[4.4.0]데크-5-엔(1,5,7-triazabicyclo[4.4.0]dec-5-ene: TBD)의 존재하에 수행하는 것이 바람직하다.The reaction is carried out in the presence of 1,5,7-triazabicyclo [4.4.0] dec-5-ene (1,5,7-triazabicyclo [4.4.0] dec-5-ene: TBD). desirable.

반응 온도는 상온 내지 60℃가 바람직하다.
As for reaction temperature, normal temperature-60 degreeC is preferable.

다른 한편으로, 본 발명은 상기 화학식 1의 3,4-디히드로퀴나졸린 유도체의 제조를 위한 신규한 중간체인 하기 화학식 6의 디아민에 관한 것이다.On the other hand, the present invention relates to a diamine of formula (6) which is a novel intermediate for the preparation of 3,4-dihydroquinazoline derivative of formula (1).

[화학식 6][Chemical Formula 6]

Figure 112011019160272-pat00011
Figure 112011019160272-pat00011

상기 화학식 6의 디아민은 하기 반응식 3에 도시된 바와 같이 제조될 수 있다. The diamine of Chemical Formula 6 may be prepared as shown in Scheme 3 below.

[반응식 3]Scheme 3

Figure 112011019160272-pat00012
Figure 112011019160272-pat00012

상기 화학식 8의 1,5-디아미노펜탄을 2 당량의 디-t-부틸 디카보네이트와 반응시킨 후 환원시켜 두 개의 말단기에 각각 메틸기가 도입된 상기 화학식 9의 화합물을 수득하고, 상기 화학식 9의 화합물을 1.5 당량의 디-t-부틸 디카보네이트와 반응시켜 상기 화학식 10의 화합물을 수득한 다음, 상기 화학식 10의 화합물을 환원시켜 상기 화학식 6의 디아민을 제조할 수 있다.The 1,5-diaminopentane of Chemical Formula 8 is reacted with 2 equivalents of di-t-butyl dicarbonate and then reduced to obtain a compound of Chemical Formula 9 having methyl groups introduced into two terminal groups, respectively, The compound of Formula 1 may be reacted with 1.5 equivalents of di-t-butyl dicarbonate to obtain a compound of Formula 10, and then the compound of Formula 10 may be reduced to prepare a diamine of Formula 6.

상기 환원 반응은 LiAlH4을 이용하는 것이 바람직하며, 상기 화학식 9의 화합물과 디-t-부틸 디카보네이트의 반응은 HCl의 존재하에 수행하는 것이 바람직하다.Preferably, the reduction reaction uses LiAlH 4, and the reaction of the compound of Formula 9 with di-t-butyl dicarbonate is preferably performed in the presence of HCl.

본 발명의 제조방법에 따르면, 화학식 1의 3,4-디히드로퀴나졸린 유도체를 공지된 방법 보다 짧은 공정에 의해 고수율로 제조할 수 있다. 아울러 본 발명의 제조방법은 고가의 시약을 사용하지 않고 공정 시간이 획기적으로 단축되어 경제적이고 대량생산에 적합하다.According to the preparation method of the present invention, the 3,4-dihydroquinazoline derivative of the formula (1) can be prepared in a high yield by a shorter process than a known method. In addition, the manufacturing method of the present invention is drastically shortened the process time without using expensive reagents, it is economical and suitable for mass production.

이하, 실시예에 의해 본 발명을 보다 구체적으로 설명하고자 한다. 이들 실시예는 오직 본 발명을 설명하기 위한 것으로 본 발명의 범위가 이들 실시예에 국한되지 않는다는 것은 당업자에게 있어서 자명하다.
Hereinafter, the present invention will be described in more detail with reference to Examples. It should be apparent to those skilled in the art that these embodiments are for illustrative purpose only and that the scope of the present invention is not limited to these embodiments.

실시예 1: 메틸 2-아미노신나메이트 (3)의 합성 Example 1 Synthesis of Methyl 2-aminocinnamate (3)

CH3OH (100mL)에 녹인 2-니트로신나믹엑시드 (2) (3.00 g, 15.53 mmol) 용액에 상온에서 95% H2SO4 (0.25 mL, 4.66 mmol)를 적가하고, 12시간 동안 (overnight) 환류하며 반응시킨 후 상온에서 냉각시켰다. 포화된 NaHCO3 수용액을 넣고 디클로로메탄으로 추출한 후, 유기층을 무수 MgSO4로 건조시키고 감압하에서 용매를 제거하여 노란색 고체인 메틸 2-니트로신나메이트 3.21 g (99%)을 얻었다.To a solution of 2-nitrocinnamic acid (2) (3.00 g, 15.53 mmol) dissolved in CH 3 OH (100 mL) was added dropwise 95% H 2 SO 4 (0.25 mL, 4.66 mmol) at room temperature, and over 12 hours (overnight). The reaction was refluxed and then cooled to room temperature. After adding saturated aqueous NaHCO 3 solution and extracting with dichloromethane, the organic layer was dried over anhydrous MgSO 4 and the solvent was removed under reduced pressure to obtain 3.21 g (99%) of methyl 2-nitrocinnamate as a yellow solid.

수득한 메틸 2-니트로신나메이트 (3.21 g, 15.53 mmol)을 EtOAc (100 mL)에 녹이고 SnCl2·2H2O (17.52 g, 77.65 mmol)를 상온에서 가한 후, 반응 혼합물을 1시간 동안 환류시켰다. 상온으로 냉각시킨 후, 반응 혼합물에 NaHCO3를 넣고 셀라이트 (celite)로 여과하였다. 물층을 EtOAc로 추출하고 모아진 유기층을 무수 MgSO4로 건조시킨 후 감압하에 용매를 제거하여 노란색 고체인 표제 화합물을 2.70 g (98%) 얻었다.The resulting methyl 2-nitrocinnamate (3.21 g, 15.53 mmol) was dissolved in EtOAc (100 mL) and SnCl 2 .2H 2 O (17.52 g, 77.65 mmol) was added at room temperature, and then the reaction mixture was refluxed for 1 hour. . After cooling to room temperature, NaHCO 3 was added to the reaction mixture, and the mixture was filtered through celite. The water layer was extracted with EtOAc, and the combined organic layers were dried over anhydrous MgSO 4, and the solvent was removed under reduced pressure to yield 2.70 g (98%) of the title compound as a yellow solid.

Mp 67 oC;Mp 67 o C;

1H NMR (400 MHz, CDCl3) δ 7.89 (d,J = 15.9 Hz, 1H, -C-CH=CH-), 7.44-6.76 (m, 4H, aromatic), 6.39 (d, J = 15.8 Hz, 1H, -C-CH=CH-), 3.83 (s,3H,-OCH 3); 1 H NMR (400 MHz, CDCl 3 ) δ 7.89 (d, J = 15.9 Hz, 1H, -CC H = CH-), 7.44-6.76 (m, 4H, aromatic), 6.39 (d, J = 15.8 Hz, 1H, -C-CH = C H- ), 3.83 (s, 3H, -OC H 3 );

13CNMR (100 MHz,CDCl3) δ 167.7, 145.6, 140.3, 131.3, 128.1, 119.8, 118.9, 117.7, 116.8, 51.7.
13 CNMR (100 MHz, CDCl 3 ) δ 167.7, 145.6, 140.3, 131.3, 128.1, 119.8, 118.9, 117.7, 116.8, 51.7.

실시예 2: 메틸 3-[2-(3-바이페닐우레이도)페닐]아크릴레이트 (4)의 합성Example 2: Synthesis of Methyl 3- [2- (3-biphenylureido) phenyl] acrylate (4)

무수 톨루엔 (100 mL)에 녹인 바이페닐-4-카르복실산 (5.00 g, 23.96 mmol) 용액에 Et3N (6.66 mL, 47.93 mmol)과 디페닐포스포릴 아자이드 (DPPA, 10.36 ml, 47.93 mmol)를 아르곤 기체하에서 넣었다. 혼합물을 상온에서 3시간 동안 교반하고 다시 100 oC에서 3시간 동안 교반하였다. 상온으로 냉각시킨 후, 실시예 1에서 수득한 화합물 (3) (4.25 g, 23.96 mmol)를 넣고 상온에서 12시간 동안 교반하였다. 반응 혼합물의 용매를 제거하고, 고체 잔여물을 CH3OH로 세척하여 흰색 고체인 표제 화합물을 7.14 g (80%) 얻었다.In a solution of biphenyl-4-carboxylic acid (5.00 g, 23.96 mmol) dissolved in anhydrous toluene (100 mL), Et 3 N (6.66 mL, 47.93 mmol) and diphenylphosphoryl azide (DPPA, 10.36 ml, 47.93 mmol) ) Was placed under argon gas. The mixture was stirred at room temperature for 3 hours and again at 100 ° C. for 3 hours. After cooling to room temperature, compound (3) (4.25 g, 23.96 mmol) obtained in Example 1 was added thereto, and the mixture was stirred at room temperature for 12 hours. The solvent of the reaction mixture was removed and the solid residue was washed with CH 3 OH to give 7.14 g (80%) of the title compound as a white solid.

Mp 189 oC;Mp 189 o C;

1H NMR (400 MHz, acetone-d 6) δ 8.54 (s, 1H, -NH-CO-), 8.08 (s, 1H, -NH-CO-), 7.95-7.17 (m, 13H, aromatic), 7.96 (d, 1H, J = 16 Hz, -C-CH=CH-), 6.52 (d, 1H,J = 16Hz, -CH=CH-CO-), 3.77(s,3H,-OCH 3); 1 H NMR (400 MHz, acetone- d 6 ) δ 8.54 (s, 1H, -N H -CO-), 8.08 (s, 1H, -N H -CO-), 7.95-7.17 (m, 13H, aromatic ), 7.96 (d, 1H, J = 16 Hz, -CC H = CH-), 6.52 (d, 1H, J = 16 Hz, -CH = C H -CO-), 3.77 (s, 3H, -OC H 3 );

13C NMR (100 MHz, DMSO-d 6) δ 169.9, 152.1, 140.4, 139.5, 137.9, 137.0, 128.9, 128.5, 127.8, 127.4, 127.0, 126.6, 125.6, 121.4, 120.9, 113.8, 59.0, 51.4.
13 C NMR (100 MHz, DMSO- d 6) δ 169.9, 152.1, 140.4, 139.5, 137.9, 137.0, 128.9, 128.5, 127.8, 127.4, 127.0, 126.6, 125.6, 121.4, 120.9, 113.8, 59.0, 51.4.

실시예 3: 메틸 3-[2-(3-바이페닐이미노메틸렌아미노)페닐]아크릴레이트 (5)의 합성Example 3: Synthesis of Methyl 3- [2- (3-biphenyliminomethyleneamino) phenyl] acrylate (5)

실시예 2에서 수득한 화합물 (4) (5.00 g, 13.43 mmol)와 Et3N (5.62 mL, 40.28 mmol)를 CH2Cl2 (100 mL)에 녹인 용액에 디브로모트리페닐포스포란 (8.50 g, 20.14 mmol)를 0 ℃에서 첨가한 후 같은 온도에서 12시간 동안 교반하였다. 물 (50 mL)을 넣고 CH2Cl2로 추출한 후 무수 MgSO4로 건조시켰다. 감압하에 용매를 제거하여 얻은 고체를 CH3OH로 세척하여 표제 화합물을 3.65 g (77%) 얻었다.Dibromotriphenylphosphorane (8.50) was dissolved in a solution of compound (4) (5.00 g, 13.43 mmol) and Et 3 N (5.62 mL, 40.28 mmol) obtained in Example 2 in CH 2 Cl 2 (100 mL). g, 20.14 mmol) was added at 0 ° C. and stirred at the same temperature for 12 hours. Water (50 mL) was added, extracted with CH 2 Cl 2 , and dried over anhydrous MgSO 4 . The solid obtained by removing the solvent under reduced pressure was washed with CH 3 OH to give 3.65 g (77%) of the title compound.

Mp 105-106 oC;Mp 105-106 o C;

1H NMR (400 MHz, CDCl3) δ 8.16 (d, 1H, J = 16 Hz,-C-CH=CH-), 7.61-7.17 (m, 1 3H, aromatic), 6.53 (d, 1H, J = 16 Hz, -CH=CH-CO-), 3.82(s, 3H-OCH 3); 1 H NMR (400 MHz, CDCl 3 ) δ 8.16 (d, 1H, J = 16 Hz, -CC H = CH-), 7.61-7.17 (m, 1 3H, aromatic), 6.53 (d, 1H, J = 16 Hz, -CH = C H -CO-), 3.82 (s, 3H-OC H 3 );

13C NMR (100MHz, CDCl3) δ 167.4, 140.3, 140.2, 138.8, 138.1, 136.9, 131.1, 128.9, 128.7, 128.2, 127.8, 127.5, 127.4, 126.9, 12.8, 125.8, 124.7, 119.3, 51.8.
13 C NMR (100 MHz, CDCl 3 ) δ 167.4, 140.3, 140.2, 138.8, 138.1, 136.9, 131.1, 128.9, 128.7, 128.2, 127.8, 127.5, 127.4, 126.9, 12.8, 125.8, 124.7, 119.3, 51.8.

실시예 4: N,N-디메틸-N'-메틸펜탄-1,5-디아민 (6)의 합성Example 4: Synthesis of N, N-dimethyl-N'-methylpentane-1,5-diamine (6)

1,5-디아미노페탄 (8) (3.0 g, 29.4 mmol)을 건조 THF (100 mL)에 녹인 후, 디-t-부틸 디카보네이트 (12.8 g, 58.7 mmol)를 건조 THF에 녹여 적가한 다음, 상온에서 24시간 동안 반응시켰다. 그런 다음, LiA1H4 (8.9 g, 0.23 mol)를 얼음용기 존재하에서 천천히 넣었다. LiA1H4를 모두 넣은 후, 12시간 동안 환류하였다. 12시간 후에 얼음용기 존재하에서 과량의 LiA1H4를 10 mL의 물로 천천히 파괴하였다. 그런 다음, 15% NaOH 수용액 10 mL를 넣고, 다시 30 mL의 물을 넣은 후 교반하였다. 셀라이트를 이용하여 여과한 후 여액을 감압하여 화합물 (9) (2.0 g, 60%)를 얻었다.1,5-diaminopetane (8) (3.0 g, 29.4 mmol) was dissolved in dry THF (100 mL), and then di-t-butyl dicarbonate (12.8 g, 58.7 mmol) was added dropwise in dry THF. The reaction was carried out at room temperature for 24 hours. Then LiA1H 4 (8.9 g, 0.23 mol) was slowly added in the presence of an ice container. After the LiA1H 4 both into, and the mixture was refluxed for 12 hours. After 12 hours, excess LiA1H 4 was slowly destroyed with 10 mL of water in the presence of an ice container. Then, 10 mL of 15% NaOH aqueous solution was added thereto, and 30 mL of water was added thereto, followed by stirring. After filtration through celite, the filtrate was reduced under reduced pressure to give compound (9) (2.0 g, 60%).

정제하지 않은 화합물 (9) (2.0 g, 15.4 mmol)를 메탄올 (50 mL)에 녹인 후, 3N 염산 (5.2 mL)을 천천히 적가하고 30분간 교반하였다. 그런 다음, 1.5 당량의 디-t-부틸 디카보네이트 (5.0 g, 23.1 mmol)을 천천히 적가하였다. 1시간 동안 반응시킨 후, 반응이 종료되면 감압조건에서 용매를 제거하였다. 반응 혼합물에서 에테르/물을 이용하여 물층으로 생성물을 추출하였다. 얻은 물층을 NaOH로 염기화시킨 후에 CH2Cl2로 추출하였다. 유기층을 황산마그네슘으로 건조, 여과 및 감압 농축하여 화합물 (10) (1.88 g, 53%)을 얻었다.The crude compound (9) (2.0 g, 15.4 mmol) was dissolved in methanol (50 mL), and then 3N hydrochloric acid (5.2 mL) was slowly added dropwise and stirred for 30 minutes. Then 1.5 equivalents of di-t-butyl dicarbonate (5.0 g, 23.1 mmol) was slowly added dropwise. After the reaction for 1 hour, the solvent was removed under reduced pressure when the reaction is complete. The product was extracted into the water layer using ether / water in the reaction mixture. The obtained water layer was basified with NaOH and extracted with CH 2 Cl 2 . The organic layer was dried over magnesium sulfate, filtered and concentrated under reduced pressure to obtain compound (10) (1.88 g, 53%).

화합물 (10) (1.88 g, 8.12 mmol)을 건조 THF에 녹인 후에, 얼음용기 존재하에서 4 당량의 LiA1H4 (1.24 g, 32.7 mmol)를 천천히 넣었다. LiA1H4를 모두 넣은 후 12시간 동안 환류하였다. 12시간 후에 얼음용기 존재하에서 과량의 LiA1H4를 1 mL의 물로 천천히 파괴하였다. 그런 다음, 15% NaOH 수용액 1 mL를 넣고, 다시 5 mL의 물을 넣은 후 교반하였다. 셀라이트를 이용하여 여과한 후 여액을 감압하여 표제 화합물을 351 mg (30%) 얻었다.After dissolving compound (10) (1.88 g, 8.12 mmol) in dry THF, 4 equivalents of LiA1H 4 (1.24 g, 32.7 mmol) was slowly added in the presence of an ice container. After adding all LiA1H 4 it was refluxed for 12 hours. After 12 hours, excess LiA1H 4 was slowly destroyed with 1 mL of water in the presence of an ice container. Then, 1 mL of 15% NaOH aqueous solution was added, 5 mL of water was added thereto, followed by stirring. After filtration through celite, the filtrate was reduced under reduced pressure to give 351 mg (30%) of the title compound.

¹H NMR (400 MHz, CDCl₃) δ 2.93 (t, J = 7.2 Hz, 2H, -CH₂-CH₂-NH-CH₃), 2.74 (t, J = 7.2 Hz, 2H, (CH₃)₂-N-CH₂-CH₂-), 2.65 (s, 3H, -NH-CH₃), 2.55 (s, 6H, (CH₃)₂-N-), 1.41-1.32 (m, 6H, -CH₂-CH₂-CH₂-CH₂-CH₂-).
¹H NMR (400 MHz, CDCl₃) δ 2.93 (t, J = 7.2 Hz, 2H, -CH₂-C H ₂-NH-CH₃), 2.74 (t, J = 7.2 Hz, 2H, (CH₃) ₂-NC H ₂-CH₂-), 2.65 (s, 3H, -NH-C H ₃), 2.55 (s, 6H, (C H ₃) ₂-N-), 1.41-1.32 (m, 6H, -CH₂- CH-CH ₂- CH ₂-CH₂-).

실시예 5: 3-바이페닐-4-일-2-[(5-N,N-디메틸아미노펜틸)-N'-메틸아미노]-4-메톡시카보닐메틸-3,4-디히드로퀴나졸린 (7)의 합성Example 5: 3-biphenyl-4-yl-2-[(5-N, N-dimethylaminopentyl) -N'-methylamino] -4-methoxycarbonylmethyl-3,4-dihydroquina Synthesis of sleepy 7

실시예 3에서 수득한 화합물 (5) (0.53 g, 1.48 mmol)를 톨루엔 (20 mL)에 녹인 용액에 상온에서 실시예 4에서 수득한 N,N-디메틸-N'-메틸펜탄-1,5-디아민 (6) (0.88 g, 2.97 mmol)을 첨가하였다. 반응 용액을 상온에서 1시간 동안 교반한 후, 1N NaOH로 염기화하고 CH2Cl2로 추출하였다. 유기층을 무수 MgSO4로 건조시키고 감압하에 용매를 제거하였다. 플래시 컬럼 크로마토그래피 (EtOAc/n-헥산/CH2Cl2=1:2:1)로 분리하여 표제 화합물을 0.74 g (99%) 얻었다.N, N-dimethyl-N'-methylpentane-1,5 obtained in Example 4 in a solution of compound (5) (0.53 g, 1.48 mmol) obtained in Example 3 in toluene (20 mL) at room temperature. -Diamine (6) (0.88 g, 2.97 mmol) was added. The reaction solution was stirred at room temperature for 1 hour, then basified with 1N NaOH and extracted with CH 2 Cl 2 . The organic layer was dried over anhydrous MgSO 4 and the solvent was removed under reduced pressure. Flash column chromatography (EtOAc / n -hexane / CH 2 Cl 2 = 1: 2: 1) afforded 0.74 g (99%) of the title compound.

1H-NMR (400 MHz, CDCl3)δ 7.50-6.88 (13H, m, Ph), 5.11 (1H, dd, J = 10.4 and 4.8 Hz, COCH2CH), 3.76 (1H, s, CH 3 -O), 3.50-3.20 (2H, m, CH3N-CH 2 ), 2.88-2.81 (4H,CH 3 -N and COCH), 2.52 (1H, dd, J = 15.6 and 4.8 Hz, COCH), 2.30-2.29 (2H, m, -NCH 2 ), 2.26 (6H, s, 2×N-CH 3 ), 1.65-1.35 (4H, m, 2×CH 2 -), 1.25-1.10 (2H, m, CH 2 -).
1 H-NMR (400 MHz, CDCl 3 ) δ 7.50-6.88 (13H, m, Ph), 5.11 (1H, dd, J = 10.4 and 4.8 Hz, COCH 2 C H ), 3.76 (1H, s, C H 3 -O), 3.50-3.20 (2H, m, CH 3 NC H 2 ), 2.88-2.81 (4H, C H 3 -N and COC H ), 2.52 (1H, dd, J = 15.6 and 4.8 Hz, COC H ), 2.30-2.29 (2H, m, -NC H 2 ), 2.26 (6H, s, 2 × NC H 3 ), 1.65-1.35 (4H, m, 2 × C H 2- ), 1.25-1.10 ( 2H, m, C H 2- ).

실시예 6: 4-(N-벤질아세트아미노)-3-(바이페닐-4-일)-2-N‘-(5-N“,N”-디메틸아미노펜틸)-N-메틸-아미노-3,4-디히드로퀴나졸린 (1)의 합성Example 6: 4- (N-benzylacetamino) -3- (biphenyl-4-yl) -2-N '-(5-N ", N" -dimethylaminopentyl) -N-methyl-amino- Synthesis of 3,4-dihydroquinazoline (1)

실시예 5에서 수득한 화합물 (7) (0.5 g, 0.77 mmol)과 벤질아민 (0.2 mL, 1.84 mmol) 및 1,5,7-트리아자바이사이클로[4.4.0]데크-5-엔 (TBD, 0.03 g, 0.23 mmol)의 혼합물을 40℃에서 12시간 동안 교반한 후 감압하에 용매를 제거하였다. 플래시 컬럼 크로마토그래피 (CH2Cl2/CH3OH/NH4OH=100:9:1)를 이용하여 분리하여 표제 화합물을 0.38 g (89%) 얻었다.Compound (7) obtained in Example 5 (0.5 g, 0.77 mmol) and benzylamine (0.2 mL, 1.84 mmol) and 1,5,7-triazabicyclo [4.4.0] dec-5-ene (TBD, 0.03 g, 0.23 mmol) was stirred at 40 ° C. for 12 h and then the solvents were removed under reduced pressure. Flash column chromatography (CH 2 Cl 2 / CH 3 OH / NH 4 OH = 100: 9: 1) afforded 0.38 g (89%) of the title compound.

1H NMR (400 MHz, CDCl3) δ 7.72-6.98 (18H, m, Ph), 5.32 (1H, dd,J = 9.1 and 4.6 Hz, COCH2CH), 4.50 (2H, d,J = 5.8 Hz, PhCH 2-), 3.50-3.20 (2H, m, CH3N-CH 2), 2.71-2.33 (4H, CH 3-N and COCH), 2.44 (1H, dd, J = 14.5 and 5.2 Hz,COCH), 2.30-2.29 (2H, m, -NCH 2), 2.21(6H, s, 2C NCH 3), 1.65-1.35 (4H, m, 2xCH 2), 1.25-1.10 (2H, m, CH 2); 1 H NMR (400 MHz, CDCl 3 ) δ 7.72-6.98 (18H, m, Ph), 5.32 (1H, dd, J = 9.1 and 4.6 Hz, COCH 2 C H ), 4.50 (2H, d, J = 5.8 Hz, PhC H 2- ), 3.50-3.20 (2H, m, CH 3 NC H 2 ), 2.71-2.33 (4H, C H 3 -N and COC H ), 2.44 (1H, dd, J = 14.5 and 5.2 Hz, COC H ), 2.30-2.29 (2H, m, -NC H 2 ), 2.21 (6H, s, 2C NC H 3 ), 1.65-1.35 (4H, m, 2xC H 2 ), 1.25-1.10 (2H , m, C H 2 );

13C NMR (100 MHz, CDCl3) δ 170.1, 153.9, 145.3, 143.8, 140.4, 138.4, 136.7, 128.8, 128.6, 128.1, 128.0, 127.8, 127.4, 127.1, 127.0, 126.2, 125.1, 122.8, 122.4, 122.2, 61.2, 59.7, 49.5, 45.2, 43.8, 41.8, 35.3, 27.1, 27.0, 24.7; 13 C NMR (100 MHz, CDCl 3 ) δ 170.1, 153.9, 145.3, 143.8, 140.4, 138.4, 136.7, 128.8, 128.6, 128.1, 128.0, 127.8, 127.4, 127.1, 127.0, 126.2, 125.1, 122.8, 122.4, 122.2 , 61.2, 59.7, 49.5, 45.2, 43.8, 41.8, 35.3, 27.1, 27.0, 24.7;

MS (FAB+), m/z (relative intensity,%) 596.7 ([M+Na]+,100), 574.7([M+H]+,30);MS (FAB +), m / z (relative intensity,%) 596.7 ([M + Na] + , 100), 574.7 ([M + H] + , 30);

MS (FAB-), m/z (relative intensity,%) 572.7 ([M-H]+,100);MS (FAB-), m / z (relative intensity,%) 572.7 ([M−H] + , 100);

HRMS (FAB+) calcd for C37H44N5O: [M+H]+=574.3546, found=574.3516.HRMS (FAB +) calcd for C 37 H 44 N 5 O: [M + H] + = 574.3546, found = 574.3516.

Claims (10)

(i) 하기 화학식 2의 2-니트로신나믹엑시드를 메탄올과 에스테르화 반응시킨 다음, 니트로기를 환원 반응시켜 하기 화학식 3의 메틸 2-아미노신나메이트를 수득하는 단계;
(ii) 하기 화학식 3의 메틸 2-아미노신나메이트를 바이페닐-4-카르복실산 및 디페닐포스포릴 아자이드와 반응시켜 하기 화학식 4의 우레아 화합물을 수득하는 단계;
(iii) 하기 화학식 4의 우레아 화합물을 탈수반응시켜 하기 화학식 5의 카보디이미드 화합물을 수득하는 단계;
(iv) 하기 화학식 5의 카보디이미드 화합물을 하기 화학식 6의 디아민과 반응시켜 하기 화학식 7의 디히드로퀴나졸린 에스테르 화합물을 수득하는 단계; 및
(v) 하기 화학식 7의 디히드로퀴나졸린 에스테르 화합물을 벤질아민과 반응시키는 단계를 포함하는 하기 화학식 1의 3,4-디히드로퀴나졸린 유도체의 제조방법:
[화학식 2]
Figure 112011019160272-pat00013

[화학식 3]
Figure 112011019160272-pat00014

[화학식 4]
Figure 112011019160272-pat00015

[화학식 5]
Figure 112011019160272-pat00016

[화학식 6]
Figure 112011019160272-pat00017

[화학식 7]
Figure 112011019160272-pat00018

[화학식 1]
Figure 112011019160272-pat00019
(i) esterifying the 2-nitrocinnamic acid of Formula 2 with methanol and then reducing the nitro group to obtain methyl 2-aminocinnamate of Formula 3;
(ii) reacting methyl 2-aminocinnamate of Formula 3 with biphenyl-4-carboxylic acid and diphenylphosphoryl azide to obtain a urea compound of Formula 4;
(iii) dehydrating the urea compound of formula 4 to obtain a carbodiimide compound of formula 5;
(iv) reacting a carbodiimide compound of formula 5 with a diamine of formula 6 to obtain a dihydroquinazolin ester compound of formula 7; And
(v) A process for preparing a 3,4-dihydroquinazolin derivative of formula 1 comprising reacting a dihydroquinazolin ester compound of formula 7 with benzylamine:
(2)
Figure 112011019160272-pat00013

(3)
Figure 112011019160272-pat00014

[Chemical Formula 4]
Figure 112011019160272-pat00015

[Chemical Formula 5]
Figure 112011019160272-pat00016

[Chemical Formula 6]
Figure 112011019160272-pat00017

(7)
Figure 112011019160272-pat00018

[Chemical Formula 1]
Figure 112011019160272-pat00019
제1항에 있어서, 단계 (i)에서 에스테르화 반응이 산 촉매의 존재하에 수행되는 것을 특징으로 하는 제조방법.The process according to claim 1, wherein the esterification reaction in step (i) is carried out in the presence of an acid catalyst. 제2항에 있어서, 산 촉매가 황산, 염산 또는 질산인 것을 특징으로 하는 제조방법.The process according to claim 2, wherein the acid catalyst is sulfuric acid, hydrochloric acid or nitric acid. 제1항에 있어서, 단계 (i)에서 환원 반응이 SnCl2H2O를 사용하여 수행되는 것을 특징으로 하는 제조방법.The process according to claim 1, wherein in step (i) the reduction reaction is carried out using SnCl 2H 2 O. 제1항에 있어서, 단계 (ii)의 반응이 염기의 존재하에 수행되는 것을 특징으로 하는 제조방법.The process according to claim 1, wherein the reaction of step (ii) is carried out in the presence of a base. 제5항에 있어서, 염기가 트리에틸아민 또는 디이소프로필에틸아민인 것을 특징으로 하는 제조방법.A process according to claim 5, wherein the base is triethylamine or diisopropylethylamine. 제1항에 있어서, 단계 (iii)의 탈수반응이 PPh3·Br2 또는 CBr4/Ph3P과 Et3N의 존재하에 수행되는 것을 특징으로 하는 제조방법.The process according to claim 1, wherein the dehydration reaction of step (iii) is carried out in the presence of PPh 3 · Br 2 or CBr 4 / Ph 3 P and Et 3 N. 제1항에 있어서, 단계 (iv)의 반응이 1,5,7-트리아자바이시클로[4.4.0]데크-5-엔의 존재하에 수행되는 것을 특징으로 하는 제조방법.The process according to claim 1, wherein the reaction of step (iv) is carried out in the presence of 1,5,7-triazabicyclo [4.4.0] dec-5-ene. 삭제delete 삭제delete
KR1020110023369A 2011-03-16 2011-03-16 Process for Preparing 3,4-Dihydroquinazoline Derivative and Intermediate therefor KR101345471B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020110023369A KR101345471B1 (en) 2011-03-16 2011-03-16 Process for Preparing 3,4-Dihydroquinazoline Derivative and Intermediate therefor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020110023369A KR101345471B1 (en) 2011-03-16 2011-03-16 Process for Preparing 3,4-Dihydroquinazoline Derivative and Intermediate therefor

Publications (2)

Publication Number Publication Date
KR20120105744A KR20120105744A (en) 2012-09-26
KR101345471B1 true KR101345471B1 (en) 2014-01-23

Family

ID=47112552

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020110023369A KR101345471B1 (en) 2011-03-16 2011-03-16 Process for Preparing 3,4-Dihydroquinazoline Derivative and Intermediate therefor

Country Status (1)

Country Link
KR (1) KR101345471B1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100902145B1 (en) * 2007-05-08 2009-06-10 동우신테크 주식회사 3,4-Dihydroquinazoline Derivatives and Anti-Cancer Agents including them

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100902145B1 (en) * 2007-05-08 2009-06-10 동우신테크 주식회사 3,4-Dihydroquinazoline Derivatives and Anti-Cancer Agents including them

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Bioorganic & Medicinal Chemistry Letters. Vol. 16, pp. 5014-5017 (2006) *
Bioorganic & Medicinal Chemistry Letters. Vol. 16, pp. 5014-5017 (2006)*

Also Published As

Publication number Publication date
KR20120105744A (en) 2012-09-26

Similar Documents

Publication Publication Date Title
RU2664643C2 (en) Process for preparation of n-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepine-4-yl)-6-methyl-quinazoline-4-amine
JP2018511653A (en) Process for producing regipassvir and derivatives thereof, and intermediate compound for producing regipassvir
WO2015037460A1 (en) METHOD FOR PRODUCING OPTICALLY ACTIVE 3-(BIPHENYL-4-YL)-2-[(t-BUTOXYCARBONYL)AMINO]PROPAN-1-OL
EA036663B1 (en) Method for preparing azoxystrobin
JP2006169244A (en) Method for producing carbamic acid ester derivative
JP5622842B2 (en) Method for producing alkylamine derivative
CN110790689B (en) Synthetic method of 1, 1-difluoro-2-isonitrile-ethyl phenyl sulfone compound
KR101345471B1 (en) Process for Preparing 3,4-Dihydroquinazoline Derivative and Intermediate therefor
CN101939289A (en) Novel process for the preparation of vorinostat
JP6695908B2 (en) Method for producing benzamide compound
KR20160027536A (en) Process for preparing an intermediate useful for the synthesis of silodosin
KR20200117952A (en) Highly enantioselective bifunctional chiral organocatalytic compound, method for preparing the same, and method for preparing non-natural gamma-amino acid from nitrocompound using thereof
WO2016199688A1 (en) Method for producing carbamate compound
CN113651715B (en) Method for synthesizing coumaroyl dopamine by one-pot method
KR100701743B1 (en) Novel Making Proces of the Bambuterol
KR100850558B1 (en) Process for preparing useful in synthesis of atorvastatin
FR2953518A1 (en) PROCESS FOR PREPARING A COMBRETASTATIN DERIVATIVE
JP2009242243A (en) alpha-HYDROXYIMINO CARBOXYLIC ACID ESTER DERIVATIVE AND METHOD FOR PRODUCING alpha-AMINO-alpha-HALOALKYL CARBOXYLIC ACID ESTER DERIVATIVE BY USING THE SAME
CN116003384A (en) Synthesis method of dabigatran etexilate important intermediate
EP3725769A1 (en) Process for the production of substituted 2-[2-(phenyl) ethylamino]alkaneamide derivatives
KR101085170B1 (en) Method of Preparing S-Rivastigmine
KR100726890B1 (en) Synthesis of Thiophene Based Units for Metal Chelation
JP4652079B2 (en) Process for producing 2,2-disubstituted ethylenediamine derivatives
KR20220145941A (en) Method for manufacturing of guanidino-benzoate sulfonic acid compound
RU2487117C1 (en) Method of producing 1,3-disubstituted urea derivatives of 1,3-dimethyladamantane

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20161215

Year of fee payment: 4

FPAY Annual fee payment

Payment date: 20171030

Year of fee payment: 5

LAPS Lapse due to unpaid annual fee